Vanda Pharmaceuticals Inc VNDA

NAS: VNDA | ISIN: US9216591084   17/10/2025
5,270 USD (0,00%)
(0,00%)   17/10/2025
Grafiek Vanda Pharmaceuticals Inc Grafiek Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals Inc in het nieuws

8 oktober 2025 · Monumental Sports & Entertainment Taps D.C.'s Own Vanda Pharmaceuticals as Founding Partner to Help Drive the Creation of Brand-New Downtown Arena · Persbericht

1 oktober 2025 · Vanda Pharmaceuticals Announces Collaborative Framework for Resolution of Disputes with the U.S. Food and Drug Administration · Persbericht

25 september 2025 · Vanda Pharmaceuticals announces the publication in PLOS One of an article titled "Melatonin agonist tasimelteon (HETLIOZ®) improves sleep in patients with primary insomnia: A multicenter, randomized, double-blind, placebo-controlled trial" · Persbericht

28 augustus 2025 · Vanda Pharmaceuticals Announces Participation at September 2025 Investor Conferences · Persbericht

28 augustus 2025 · Vanda Pharmaceuticals Announces FDA Granted Orphan Drug Designation for VGT-1849B, a Novel and Selective Candidate for the Treatment of Polycythemia Vera · Persbericht

18 augustus 2025 · In a Major Win for Vanda, a Federal Appeals Court Overturns FDA's Order Denying Approval of Hetlioz for the Treatment of Jet Lag Disorder · Persbericht

31 juli 2025 · Vanda Pharmaceuticals Reports Second Quarter 2025 Financial Results · Persbericht

23 juli 2025 · Vanda Pharmaceuticals to Announce Second Quarter 2025 Financial Results on July 31, 2025 · Persbericht

10 juni 2025 · Vanda Pharmaceuticals Announces First Patient Dosed in a Trial Evaluating VCA-894A in Charcot-Marie-Tooth disease Type 2S · Persbericht

27 mei 2025 · Vanda Pharmaceuticals Announces Presentation at 2025 ASCP Annual Meeting · Persbericht

Profiel Vanda Pharmaceuticals Inc

Biotechnologie
Fabricage van farmaceutische preparaten
Gezondheidstechnologie
Productie

Website: www.vandapharma.com

Hoofdzetel: Washington, Washington Dc vlag Verenigde Staten

Mijn selecties